Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$74.18−3.48 (-4.48%)
Close on Nov 17, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences total assets
Total assets on the balance sheet at the end of each period.
Inhibrx Biosciences's total assets was $220.29M at Sep 30, 2026. For fiscal 2025 it was $146.48M, down 19.0% from the year before. The highest annual figure on record is $307.89M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.48M | -19.0% |
| FY2024 | Dec 31, 2024 | $180.77M | -41.3% |
| FY2023 | Dec 31, 2023 | $307.89M | +5.9% |
| FY2022 | Dec 31, 2022 | $290.88M | +93.3% |
| FY2021 | Dec 31, 2021 | $150.45M | +4.7% |
| FY2020 | Dec 31, 2020 | $143.74M | +442.6% |
| FY2019 | Dec 31, 2019 | $26.49M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $220.29M | +24.1% |
| Q2 FY2026 | Jun 30, 2026 | $154.22M | -27.3% |
| Q1 FY2026 | Mar 31, 2026 | $183.97M | -24.2% |
| Q4 FY2025 | Dec 31, 2025 | $146.48M | -19.0% |
| Q3 FY2025 | Sep 30, 2025 | $177.47M | -20.3% |
| Q2 FY2025 | Jun 30, 2025 | $212.12M | -17.9% |
| Q1 FY2025 | Mar 31, 2025 | $242.64M | -15.9% |
| Q4 FY2024 | Dec 31, 2024 | $180.77M | -41.3% |
| Q3 FY2024 | Sep 30, 2024 | $222.56M | -40.3% |
| Q2 FY2024 | Jun 30, 2024 | $258.42M | +21.2% |
| Q1 FY2024 | Mar 31, 2024 | $288.58M | +13.7% |
| Q4 FY2023 | Dec 31, 2023 | $307.89M | +5.9% |
| Q3 FY2023 | Sep 30, 2023 | $372.73M | +126.1% |
| Q2 FY2023 | Jun 30, 2023 | $213.17M | +10.3% |
| Q1 FY2023 | Mar 31, 2023 | $253.72M | +57.4% |
| Q4 FY2022 | Dec 31, 2022 | $290.88M | +93.3% |
| Q3 FY2022 | Sep 30, 2022 | $164.85M | +27.6% |
| Q2 FY2022 | Jun 30, 2022 | $193.21M | +36.2% |
| Q1 FY2022 | Mar 31, 2022 | $161.18M | +29.5% |
| Q4 FY2021 | Dec 31, 2021 | $150.45M | +4.7% |
| Q3 FY2021 | Sep 30, 2021 | $129.18M | -10.0% |
| Q2 FY2021 | Jun 30, 2021 | $141.89M | +435.6% |
| Q1 FY2021 | Mar 31, 2021 | $124.50M | – |
| Q4 FY2020 | Dec 31, 2020 | $143.74M | – |
| Q3 FY2020 | Sep 30, 2020 | $143.55M | – |
| Q4 FY2019 | Dec 31, 2019 | $26.49M | – |
See a number that looks wrong?